First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

But it remains to be seen how long this can continue because of dwindling sales of its inflammatory disease drug Remicade and a looming threat to Zytiga. Zytiga (abiraterone), approved since 2011 ...

Zytiga sales have been romping away of late in ... Analysts have suggested that the new indication could add $1 billion or so to the drug’s sales by 2020, potentially pushing it above the ...

Monte Rosa Therapeutics' stock falls as MRT-2359 faces challenges in targeting CRPC. Click here to read an analysis of GLUE ...

Drug screening is the process by which potential drugs are identified and optimized before selection of a candidate drug to progress to clinical trials. It can involve screening large libraries of ...

Blue chip stocks are from well-established companies with reliable profit records. They offer stable dividends and are favored for long-term investment security. Diversifying portfolios with blue ...

After hours: March 26 at 7:46:35 PM EDT Loading Chart for DRUG ...

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer ...